Francesca Citron
Overview
Explore the profile of Francesca Citron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scafetta G, Rampioni Vinciguerra G, Giglio S, Faruq O, Cirombella R, Segatto I, et al.
J Exp Clin Cancer Res
. 2025 Mar;
44(1):96.
PMID: 40082972
Breast cancer ranks as the most prevalent form of cancer globally. Currently, advanced screening methods have significantly improved early detection rates. These achievements have led to more non-invasive cancer diagnoses...
2.
Perelli L, Zhang L, Mangiameli S, Giannese F, Mahadevan K, Peng F, et al.
Nature
. 2025 Mar;
PMID: 40044861
Mesenchymal plasticity has been extensively described in advanced epithelial cancers; however, its functional role in malignant progression is controversial. The function of epithelial-to-mesenchymal transition (EMT) and cell plasticity in tumour...
3.
WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer
Citron F, Ho I, Balestrieri C, Liu Z, Yen E, Cecchetto L, et al.
bioRxiv
. 2024 Nov;
PMID: 39484624
It is unclear how cells counteract the potentially harmful effects of uncoordinated DNA replication in the context of oncogenic stress. Here, we identify the WRAD (WDR5/RBBP5/ASH2L/DPY30) core as a modulator...
4.
Takeda M, Theardy M, Sorokin A, Coker O, Kanikarla P, Chen S, et al.
bioRxiv
. 2024 Aug;
PMID: 39211217
The therapeutic benefit of recently developed mutant KRAS (mKRAS) inhibitors has been limited by the rapid onset of resistance. Here, we aimed to delineate the mechanisms underlying acquired resistance to...
5.
Cortesi A, Gandolfi F, Arco F, Di Chiaro P, Valli E, Polletti S, et al.
Sci Adv
. 2024 Mar;
10(13):eadk5386.
PMID: 38536927
While pancreatic ductal adenocarcinomas (PDACs) are addicted to KRAS-activating mutations, inhibitors of downstream KRAS effectors, such as the MEK1/2 kinase inhibitor trametinib, are devoid of therapeutic effects. However, the extensive...
6.
Ho I, Li C, Wang F, Zhao L, Liu J, Yen E, et al.
Sci Adv
. 2024 Mar;
10(11):eadd9342.
PMID: 38478609
Tumors represent ecosystems where subclones compete during tumor growth. While extensively investigated, a comprehensive picture of the interplay of clonal lineages during dissemination is still lacking. Using patient-derived pancreatic cancer...
7.
Perelli L, Zhang L, Mangiameli S, Russell A, Giannese F, Peng F, et al.
bioRxiv
. 2023 Oct;
PMID: 37786705
Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role...
8.
Perelli L, Carbone F, Zhang L, Huang J, Le C, Khan H, et al.
Nat Cancer
. 2023 Jun;
4(7):984-1000.
PMID: 37365326
Molecular routes to metastatic dissemination are critical determinants of aggressive cancers. Through in vivo CRISPR-Cas9 genome editing, we generated somatic mosaic genetically engineered models that faithfully recapitulate metastatic renal tumors....
9.
Segatto I, Rampioni Vinciguerra G, Pellarin I, DallAcqua A, Berton S, Citron F, et al.
Cancer Commun (Lond)
. 2023 Jun;
43(7):844-849.
PMID: 37337406
No abstract available.
10.
Califano D, Gallo D, Rampioni Vinciguerra G, De Cecio R, Arenare L, Signoriello S, et al.
Cancers (Basel)
. 2021 Oct;
13(20).
PMID: 34680301
Background: Epithelial ovarian cancer (EOC) is a rare, highly lethal disease. In a subset of high grade EOC patients, maintenance therapy with the antiangiogenic drug Bevacizumab (BEV) is a valuable...